🟢 Zevra Therapeutics is trading 7% up in pre-market as catalyst remains unclear

Zevra Therapeutics is trading 7.03% up in pre-market at $10.50 on October 26, with the catalyst unclear.

• The supplied price context compares the pre-market price with the October 23 close of $9.81.
• No fresh company-specific announcement explaining the move was found. The latest company release located, dated October 20, only scheduled third-quarter results for November 3.
• Major U.S. indices are modestly higher, but below the stated threshold for attributing Zevra’s move to broader market strength.